Delcath SystemsDCTH
DCTH
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Employees: 76
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
279% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $558K
100% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 19
69% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 29
28% more capital invested
Capital invested by funds: $184M [Q1] → $236M (+$52.3M) [Q2]
18% more funds holding
Funds holding: 98 [Q1] → 116 (+18) [Q2]
7.28% more ownership
Funds ownership: 45.18% [Q1] → 52.46% (+7.28%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
125%
upside
Avg. target
$28
152%
upside
High target
$31
179%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 179%upside $31 | Buy Maintained | 7 Aug 2025 |
Stephens & Co. Sudan Loganathan | 125%upside $25 | Overweight Reiterated | 23 Jun 2025 |
Financial journalist opinion
Based on 7 articles about DCTH published over the past 30 days
Neutral
Business Wire
5 days ago
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 4, 2025, in Boston, MA H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, in New York, NY About Delcath Systems, Inc., HEPZATO KIT and CHE.
Neutral
Business Wire
1 week ago
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The Phase 2 trial will evaluate the safety and efficacy of HE.
Neutral
Seeking Alpha
2 weeks ago
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard J. Michel - CEO & Director Kevin Muir - Corporate Participant Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Bill Morgan - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Positive
The Motley Fool
2 weeks ago
Delcath (DCTH) Q2 Revenue Jumps 210%
Delcath (DCTH) Q2 Revenue Jumps 210%
Positive
Zacks Investment Research
2 weeks ago
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.48 per share a year ago.
Neutral
Business Wire
2 weeks ago
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in.
Neutral
Business Wire
4 weeks ago
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of.
Neutral
Business Wire
1 month ago
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and.
Neutral
Business Wire
1 month ago
Delcath Systems to Host Second Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 20.
Neutral
Zacks Investment Research
1 month ago
Is the Options Market Predicting a Spike in Delcath Systems Stock?
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Charts implemented using Lightweight Charts™